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PURPOSE. Previous research has shown atrophy of visual cortex can occur in retinotopic
representations of retinal lesions resulting from eye disease. However, the time course of
atrophy cannot be established from these cross-sectional studies, which included patients
with longstanding disease of varying severity. Our aim, therefore, was to measure visual
cortical structure over time in participants after onset of unilateral visual loss resulting from
AMD.
METHODS. Inclusion criteria were onset of acute unilateral neovascular AMD with bilateral dry
AMD based on clinical examination. Therefore, substantial loss of unilateral visual input to
cortex was relatively well-defined in time. Changes in cortical anatomy were assessed in the
occipital lobe as a whole, and in cortical representations of the lesion and intact retina, the
lesion and intact projection zones, respectively. Whole brain, T1-weighted magnetic
resonance imaging was taken at diagnosis (before antiangiogenic treatment to stabilize the
retina), during the 3- to 4-month initial treatment period, with a long-term follow-up
approximately 5 (range 3.8–6.1 years) years later.
RESULTS. Significant cortical atrophy was detected at long-term follow-up only, with a
reduction in mean cortical volume across the whole occipital lobe. Importantly, this
reduction was explained by cortical thinning of the lesion projection zone, which suggests
additional changes to those associated with normal aging. Over the period of study,
antiangiogenic treatment stabilized visual acuity and central retinal thickness, suggesting that
the atrophy detected was most likely governed by long-term decreased visual input.
CONCLUSIONS. Our results indicate that consequences of eye disease on visual cortex are
atrophic and retinotopic. Our work also raises the potential to follow the status of visual
cortex in individuals over time to inform on how best to treat patients, particularly with
restorative techniques.
Keywords: magnetic resonance imaging, age-related macular degeneration, visual cortex,
cortical thinning
It has recently emerged that eye disease can result insecondary structural changes within primary visual cortex.
This is true whether the eye disease is congenital, for example
in ocular albinism,1 or acquired, for example in AMD.2 Most
commonly, atrophy demonstrated by a reduction in cortical
thickness or volume is reported in the retinotopic representa-
tion of the lesions that are a consequence of the disease.1–8
Conversely, some studies have reported atrophy in retinotopic
representations of intact but not lesioned retina in monocularly
blind9 and AMD patients,7 whereas others revealed significant
thickening of cortical representations of the intact retina,
believed to be a compensatory phenomenon.10 Controversy,
therefore, remains over the exact nature of the response of
visual cortex to retinal disease and furthermore the timing of
such changes.
AMD is an excellent model to study the consequences of
vision deprivation, as it leads to a loss of retinal input to the
cortical representation of the central visual field. However, the
most common form of the disease progresses slowly, and onset
of visual loss is a challenge to pinpoint in time. However, the
neovascular (nvAMD) form of the disease, characterized by
fluid leakage and hemorrhage in the central macula, has an
acute onset, therefore visual loss is well-defined.11 NvAMD
generally manifests unilaterally, with disease onset in the
second eye occurring in 50% of patients within 3 years after
unilateral loss.12
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To assess the time course of structural changes to visual
cortex resulting from a loss of input, we recruited individuals
recently diagnosed with onset of acute unilateral nvAMD who
had established bilateral retinal disease. As a result, a significant
unilateral change of input to visual cortex was well-defined in
time.
NvAMD affects 40,000 new people in the United Kingdom
every year,13 and when left untreated, leads to severe sight
impairment. Current treatment involves regular intraocular
anti-VEGF injections that restore approximately half the
initially lost visual acuity14–16 by halting leakage, therefore
decreasing central retinal thickness.16–18 Following an initial
improvement of visual acuity by month 3, a long-term slow
decline in visual acuity can be observed.17,19,20 The patients
we tested received standard treatment to preserve and stabilize
vision.
This study aimed to observe the short- and long-term nature
of visual cortical changes in the context of unilateral visual loss
due to nvAMD. Previous studies focused on testing patients
with established bilateral disease, between 1 and 42 years
postonset.2–4,7,10 Therefore, our first objective was to deter-
mine whether cortical changes occurred over a short timescale
of 3 months. The second objective, met by the opportunity to
follow patients long-term, was to determine what changes
occurred several years after the acute onset of unilateral
nvAMD. The third objective was to establish whether cortical
changes were atrophic and if they were specific to the cortical
representation of the retinal lesion.
MATERIALS AND METHODS
Participants
Written informed consent was obtained from all participants.
This study followed the tenets of the Declaration of Helsinki
with approval granted by York Neuroimaging Centre Research,
Ethics and Governance Committee and the NHS Research
Ethics Committee (IRAS: 27966, 199112).
Ten participants were recruited from York Teaching
Hospital NHS Foundation Trust. Inclusion criteria were onset
of acute unilateral nvAMD with bilateral dry AMD based on
clinical examination. Thus, a significant reduction in input to
visual cortex from unilateral disease was well-defined in time.
Recruitment took place between January 2011 and November
2013. Routine clinical treatment was administered in accor-
dance with guidance from the National Institute of Health and
Clinical Excellence.21
Initial assessments and magnetic resonance imaging (MRI)
were carried out before commencing routine anti-VEGF
treatment for nvAMD, with short-term assessments taking
place a mean of 3.5 months (range, 3–4 months) later in all 10
participants. Long-term assessments were carried out a mean
of 4.8 years (range, 3.8–6.1 years) after diagnosis in seven
participants in this group, because two participants did not
join the follow-up component of the study for long-term
assessments and one died. Our analysis was therefore restricted
to assessing those seven patients in whom we had measures at
all time points. The mean age of participants at baseline was
73.5 years (range, 67.1–81.5 years), increasing to 77.9 years
(range, 73.1–86.1 years) at follow-up (Table).
Design
In this longitudinal study, structural MRI was acquired at three
intervals: a baseline assessment took place before participants
received the first anti-VEGF treatment (month 0), a short-term
assessment took place a mean of 3.5 months post-baseline,
with a long-term assessment occurring a mean of 4.8 years
post-baseline (Table). Routine clinical assessments, detailed
below, coincided with the MRI visits.
Procedures
MRI. Structural MRI was acquired using an eight-channel
phased-array head coil tuned to 127.4 MHz, on a GE Healthcare
(Little Chalfont, UK) 3-Tesla Signa HD Excite scanner. One T1-
weighted anatomical volume was acquired (repetition time, 8
ms; echo time, 3 ms; inversion time, 450 ms; voxel size, 1.133
1.133 1 mm3, flip angle, 208; 2563 256 matrix; field of view,
290 mm). All participants were instructed to lie as still as
possible during the scan. Foam padding was used around the
head to minimize movement, with earplugs provided to
protect against scanner noise.
Analysis. Cortical reconstruction and volumetric segmen-
tation were performed using the Freesurfer analysis suite
(version 5.3, available at: http://surfer.nmr.mgh.harvard.edu/).
This process includes removal of non-brain tissue, intensity
normalization,22 tessellation of the gray/white matter bound-
ary, automated topology correction23,24 surface deformation
following intensity gradients to optimally place the gray/white
matter and gray/cerebrospinal fluid boundaries at the location
where the greatest shift in intensity defines the transition to
the other tissue class.
Cortical anatomy was assessed in two ways with the
following rationale. We first assessed gray matter volume of
occipital cortex. This coarse measurement has the advantage of
not being susceptible to individual differences in the cortical
representations of the visual field while also capturing
representations outside primary visual cortex. At the same
time, however, analysis of the whole occipital cortex does not
allow hypotheses concerning the retinotopic nature of cortical
changes. We turned, therefore, to a more focused region of
interest (ROI) analysis, gathering information explicitly testing
TABLE. Participant Demographics
Participant Sex
Treated
Eye
Age, y MRI Visit
Baseline
Long-Term
Assessment
Short-Term
Assessment, mo
Long-Term
Assessment, y
P3 Male Right 67.11 73.10 3 6.01
P5 Female Right 75.01 79.09 3 4.08
P6 Male Right 81.05 86.01 4 4.08
P7 Male Right 71.04 75.09 3 4.05
P8 Female Right 70.00 73.10 4 3.10
P9 Female Right 70.07 74.03 4 4.10
P10 Male Left 79.00 82.08 3 3.08
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regions of primary visual cortex representing lesioned and
intact retina. The occipital pole and calcarine sulcus were
selected, as they coincide with the lesion and intact projection
zones for individuals with central visual loss. In defining such
regions on the cortical surface, cortical thickness offers a
sensible way to gauge the status of the visual representation
that can be compared over time. Our target areas of the brain
were defined using Freesurfer’s Destrieux Atlas using the
following parcellations: occipital cortex: 2, 11, 19, 20, 22, 42,
44, 51, 57, 58, 59, 65; lesion projection zone: 42; intact
projection zone: 44.25
Mean gray matter volume was extracted from each
parcellation within the occipital cortex ROI, from both the
left and right hemispheres. An average across hemispheres was
then calculated for each participant, creating the final entire
occipital cortex ROI. A paired-samples t-test assessed changes
in cortical volume among the three intervals. Mean cortical
thickness was extracted following this same procedure for the
lesion and intact projection zones, calculated as the shortest
distance between the gray/white matter boundary and the
gray/cerebrospinal fluid boundary at each vertex across the
cortex in millimeters, averaged over all vertices within each
ROI (see Fig. 1). A paired-samples t-test assessed changes in
cortical thickness within each ROI among the same three
intervals.
Routine Clinical Assessments. Best-corrected visual
acuity and central retinal thickness were acquired in all seven
participants at all time points
Best-Corrected Visual Acuity. Standard clinical visual
acuity was measured in an illuminated room at 4 m, with the
participant’s spectacle correction in each eye using an ETDRS
(Early Treatment Diabetic Retinopathy Study) letter chart.26 If
participants were able to read four or more of the five letters
on the first line of the chart they were asked to continue
reading down the chart until they could read fewer than three
letters on a single line. At this point, the total number of letters
read correctly was recorded and an additional 30 letters were
added to the total. If participants were unable to read four
letters correctly on the first line, they were brought to 1 m and
asked to continue reading down the chart until they could read
fewer than three letters on a single line. Thirty letters were not
added to the final ETDRS score in this circumstance.
Central Retinal Thickness. Effectiveness of anti-VEGF
treatment in reducing the consequence of choroidal neovas-
cularization over time can be measured using central retinal
thickness. A reduction in central retinal thickness will indicate
resolution of the edema due to treatment. This was measured
using 1 mm3 subfield central retinal thickness with spectral-
domain optical coherence tomography (Cirrus OCT; Carl Zeiss
Meditec, Dublin, CA, USA). A standard macular cube (128 3
256 3 518) assessment took place in an illuminated room,
acquiring retinal images through dilated pupils for the treated
and untreated eyes of each participant.
Analysis. Changes in best-corrected visual acuity and
central retinal thickness were analyzed for the treated and
untreated eyes at each session. As ETDRS letter scores and
central retinal thickness values did not pass tests for normality
(Shapiro-Wilk, P < 0.001), a Wilcoxon signed rank test
assessed changes over time.
RESULTS
MRI
Our first and second objectives set out to determine whether
cortical changes occurred within the initial treatment period
following the onset of unilateral nvAMD (short-term) and what
cortical changes occurred over time (long-term). Compared
with baseline, we reveal no significant changes in cortical
volume at the short-term assessment (31,580 mm3, t[6] ¼
0.757, P ¼ 0.478); however, there is a significant reduction in
cortical volume at long-term follow-up (31,767 mm3 versus
28,639 mm3, t[6]¼ 3.033, P¼ 0.023); indeed, six of the seven
participants showed a reduction in volume. There was also a
significant difference in cortical volume between the short-
term and long-term assessments (t[6]¼ 2.689, P¼ 0.036) (Fig.
2B).
We next asked whether changes in volume were reflected
by cortical atrophy: a thinning of cortex in identifiable
retinotopic representations of the retinal lesion. The two
regions we selected showed different results (Figs. 2C, 2D). In
the intact projection zone, mean cortical thickness changed
very little (Fig. 2C); neither short-term (1.81 mm, t[6]¼ 1.218,
P ¼ 0.269) nor long-term (1.76 mm, t[6] ¼ 1.021, P ¼ 0.347)
assessments yielded significant differences compared with
baseline (1.82 mm). There was also no significant difference
between the short- or long-term assessments (t[6]¼ 0.793, P¼
0.458). In contrast, the lesion projection zone was significantly
thinner at the long-term (1.94 mm, t[6]¼2.389, P¼0.027, one-
tailed), but not short-term (2.08 mm, t[6] ¼ 1.857, P ¼ 0.113)
assessments compared with baseline (2.11 mm), with a
significant difference between the short- and long-term
assessments (t[6] ¼ 2.467, P ¼ 0.025). Although there is not
a significant interaction between timepoint and ROI, these data
are suggestive that cortical atrophy is a feature present at long-
term follow-up and larger in the cortical representation of the
lesioned retina.
While results indicate anatomical changes in visual areas of
the brain are atrophic and retinotopic, we wanted to check
whether age-dependent changes in the whole brain explained
any effects detected. Cortical thinning associated with natural
aging is well documented, although there is some discrepancy
whether cortical thinning of primary visual cortex occurs with
increasing age27,28 or not.29,30 Griffis et al.31 reported age-
dependent cortical thinning specific to peripheral but not
central representations of visual cortex. To investigate whether
reductions in mean thickness observed in this study are not
simply a consequence of natural aging, a linear regression
analysis investigated changes to the lesion and intact projection
zones in relation to changes to the whole brain. Excluding the
occipital lobes, changes in the whole brain significantly
accounted for 65% of the variance observed in the intact
projection zone, (F1,6 ¼ 9.28, P ¼ 0.029) but only 31% of the
variance in the lesion projection zone (F1,6¼ 2.32, P¼ 0.189).
Although there was no significant difference between the two
FIGURE 1. T1-weighted MRI image showing the boundary between the
white and gray matter surface, referred to as the white surface (yellow
line) and the gray matter and cerebrospinal fluid, referred to as the pial
surface (red line). The distance between the white and pial surfaces
gives the thickness at each location of cortex (white line).
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ROIs, because the whole-brain effects accounted for more of
the variance in the intact projection zone, the data are
suggestive that the reductions in cortical thickness of the
lesion projection zone are due to decreased retinal input rather
than aging.
Disease Progression Over Time
What factors might determine the changes we observed in
visual cortex? If the retinal lesions remain relatively stable over
time, it is likely that cortical atrophy was a result of the
duration of reduced input to cortex. However, if the retinal
lesion progresses over time, we would be unable to dissociate
the effects of disease progression and time on cortical atrophy.
To monitor disease progression, measures of visual acuity and
central retinal thickness were taken, coinciding with the MRI
timepoints.
Visual acuity measures are shown in Figure 3A. Median
acuity across the seven participants was below the normal
range in both treated and untreated eyes due to longstanding
vision loss associated with bilateral dry AMD. Short-term
assessments show visual acuity increased in the treated eye
compared with baseline but not significantly (T2 versus T1: z¼
1.690, P ¼ 0.091). At long-term follow-up, acuity was still
improved relative to baseline, but again not significantly (T3
versus T1: z ¼0.676, P ¼ 0.499). A similar pattern of results
was observed for the untreated eye, with no significant
changes in acuity between baseline and short-term (T2 versus
T1: z¼1.951, P¼ 0.051), or baseline and long-term follow-up
(T3 versus T1: z¼0.169, P¼ 0.866). As can be seen in Figure
3C, a decrease in visual acuity is evident in the untreated eye
for five of seven participants between the short- and long-term
assessment (T2 versus T3). Although the changes are not
significant, the gradual decline in visual acuity could indicate
changes in cortical input over time.
We also tracked any changes in retinal anatomy with
treatment by measuring central retinal thickness as an
indicator of resolved edema (Fig. 3D). Compared with baseline,
there was a significant decrease in central retinal thickness at
the short-term assessment in the treated eye (T2 versus T1: z¼
2.366, P ¼ 0.018), which remained significant at long-term
follow-up (T3 versus T1: z ¼ 2.366, P ¼ 0.018). For the
untreated eye, although a decrease in central retinal thickness
was observed in five of seven participants, this was not
significant, either between baseline and short-term (T2 versus
T1: z¼0.254, P¼ 0.799) or baseline and long-term follow-up
(T3 versus T1: z ¼ 0.507, P ¼ 0.612) with data remaining
within the normal range.
Taken together, measures of visual function and retinal
anatomy appear to indicate that although vision was subnormal
in both eyes, it was largely stable over the period of our study.
This suggests that treatment was successful in halting disease
progression in the treated eye with central retinal thickness
indicating resolution of the edema. Nevertheless, a gradual
decline in both eyes in some participants means we cannot
assert that there is no change to the input to cortex over time.
DISCUSSION
This study shows, for the first time, the time course of
structural changes to visual cortex following the onset of acute
unilateral vision loss due to nvAMD. We report that atrophy
(shrinkage) of visual cortex, detectable in a small number of
individuals followed longitudinally, is also retinotopic as it was
detected in the representation of the central visual field, that is,
the macular lesion projection zone. Atrophy was not detected
over the initial treatment period of 3 to 4 months but
developed over several years.
Our findings reinforce the evidence for retinotopic and
atrophic changes in the brain following eye disease.1–8
FIGURE 2. ROIs and their anatomical properties. (A) Surface reconstruction of a template brain with the occipital lobe (blue), lesion projection
zone (red), and intact projection zone (green). Note that the latter two ROIs constitute elements of the larger occipital lobe ROI. (B) Volume of gray
matter measured in the occipital lobe ROI at the three times of measurement. T1 refers to the baseline measure, T2 refers to the short-term
assessment, and T3 refers to the long-term assessment. Also plotted is the cortical thickness of gray matter detected within the intact projection
zone (C) and lesion projection zone (D) ROIs at three times of measurement. Line graphs for B–D represent individual changes in cortical structure
for each participant at each time point. In B–D, statistically significant differences at P < 0.05 are indicated with an * and error bars represent 6 1
SEM.
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Converging evidence suggests that when retinal disease
occurs, changes to visual cortex emerge in retinotopic
representations of the retinal lesion. For example, albinism
appears to result in changes at or near the occipital pole
reflecting foveal hypoplasia,1 and in an elegant study compar-
ing individuals affected by glaucoma with peripheral field
defects and macular degeneration with central visual defects,
cortex was affected in regions corresponding to the represen-
tations of the affected visual fields.2 Further research in central
visual field defects arising from juvenile- and AMD also reveal
atrophic changes in visual cortex and underlying white
matter.3 The former appeared most pronounced in posterior
visual cortical locations consistent with a retinotopic locus for
the effect. However, these studies use cohorts of patients with
bilateral vision loss. We find that even with significant
unilateral loss, volume of the occipital cortex is reduced with
a specific decrease in mean cortical thickness in the
retinotopic representation of the retinal lesion.
In contrast to most studies reporting cortical loss following
retinal disease, one study has reported significant thickening of
retinotopic representations of the intact retina, which was
attributed to potential compensatory mechanisms.10 As with
many other studies, the patients had bilateral vision loss,
thereby increasing the need for compensatory mechanisms.
However, the participants reported in this current study had
predominantly unilateral vision loss, limiting the need for a
compensatory mechanism, consistent with the lack of a
significant change in representations of intact retina.
Our results also provide evidence for key elements that
have not been addressed by previous investigations. Former
studies have been cross-sectional, so although accumulating
evidence of cortical loss has been relatively strong, there
remained the possibility that cohorts of patients with visual
deficits also may have comorbid brain properties differentiat-
ing them from control cohorts. Our longitudinal study
demonstrates that atrophic changes can be observed within a
group of patients followed over time.
We first asked whether changes occurred over a period of 3
to 4 months, which we believe is shorter than that previously
assessed. We detected no change at this early stage, offering
some reassurance that changes in the status of visual cortex
detectable with MRI are not rapid. Most cross-sectional studies
tested patients who had established visual loss between 1 and
42 years’ duration.2–4,7,10 It would appear, therefore, that
atrophic changes in visual cortex due to retinal disease may
emerge between 3 and 12 months after disease onset. Future
longitudinal studies would benefit from assessing the anatomy
of visual cortex during the first 24 months after visual loss to
characterize better the time course of brain changes. Our long-
term follow-up successfully detected retinotopic atrophy,
which has featured in the literature. However, the fact that
such changes were detectable in such a small sample indicates
that following individual patients over time may be a valuable
way of assessing the status of visual cortex after vision loss.
As mentioned above, previous literature has primarily
addressed cortical changes following bilateral retinal loss.
However, some studies have found structural changes follow-
ing unilateral loss. Previous studies have reported that
monocular enucleation performed early in development results
in shrinkage of ocular dominance columns33–35 and reduced
white matter connections.36 Moreover, early unilateral func-
tional loss due to amblyopia has also been shown to result in
structural changes to primary visual cortex.37 Taken together,
these studies suggest that changes to visual cortex can occur as
a result of both anatomical and functional unilateral loss
occurring early in development. Importantly, we demonstrate
that cortical changes can follow unilateral loss of input in
adulthood when the visual system has reached maturity.
Finally, routine clinical assessments highlighted the effec-
tiveness of anti-VEGF treatment for nvAMD. In all but one
participant, vision was subnormal in both eyes but remained
relatively stable over time, consistent with previous literature
studying larger cohorts.16–18 Although visual acuity and central
retinal thickness did not indicate significant changes in both
eyes over time, we cannot rule out entirely the possible
contribution of disease progression in either or both eye to the
cortical atrophy we observe.
Significant thinning of visual cortex may ultimately limit the
success of restorative treatments for eye disease. At present,
such treatments are limited by the quality of information
generated at the retina,38,39 or indeed fed to the cortex
directly.40,41 However, as the quality of visual information
increases, the reliance on functional properties of visual cortex
will come into play. For example, it has been proposed that
cortical plasticity would be required to process the limited
visual inputs that can be restored.38 However, it is not known
whether atrophy can be reversed, or whether sufficient
cortical plasticity can be achieved once functional input is
restored.
Our current results cannot inform whether atrophy reflects
degenerative processes in the cortex. Anterograde transsynap-
tic degeneration has been reported within visual cortex in
FIGURE 3. Clinical assessments. (A) Box plots showing visual acuity
performance measured in ETDRS letter score for the treated eye
(orange) and the untreated eye (cyan). Horizontal dashed line
represents an ETDRS score of 84 letters, equivalent to 6/6 Snellen
acuity, or 0.0 logMAR. (D) Box plots showing changes in central retinal
thickness for the treated eye (orange) and the untreated eye (cyan).
Horizontal dashed lines represent a healthy central retinal thickness
range for the Cirrus SD-OCT machine.32 Horizontal lines represent the
median, the upper and lower whiskers represent scores outside the
middle 50%, whereas outliers are shown as points. Line graphs show
individual changes in performance over time for each participant for
the treated eye (B, E) and the untreated eye (C, F). Black arrows on
plots B and C represent an ETDRS score of 84 letters, equivalent to 6/6
Snellen acuity, or 0.0 logMAR, whereas on plots E and F they represent
a healthy central retinal thickness range for the Cirrus SD-OCT
machine.32 All assessments were measured at three time points: T1
(baseline), T2 (short-term), and T3 (long-term assessment).
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patients following retinal disease/damage (for a review, see Ref.
42). Retrograde transsynaptic degeneration has also been
observed; when cortex is lesioned, retinal ganglion cell
numbers reduce in regions projecting to the lesioned part of
cortex.43–47 It may be valuable therefore to probe visual cortex
for measures that can track degeneration, perhaps using
magnetic resonance spectroscopy to assess neurochemical
signatures of necrosis or apoptosis.
We conclude that longstanding unilateral loss of input to
visual cortex results in significant atrophy. However, there is a
window, at least within 3 to 4 months after diagnosis, during
which no detectable atrophy was present. This finding
indicates that detrimental changes in visual cortex emerge
relatively slowly.
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